Sphingolipid-neutralizing molecular therapy reduces psychosine cytotoxicity in Krabbe disease

Key Points

• Molecular therapy effectively reduces psychosine cytotoxicity in Krabbe disease, targeting sphingolipids.
• Evidence shows a significant decrease in cell death rates linked to psychosine exposure in treated models.
• Assessment involves in vitro analysis of cell responses to molecular therapy addressing psychosine toxicity.
• Findings may indicate potential for new therapeutic strategies to combat neurodegeneration in Krabbe disease.